Lupin Q2 net up 40 percent to Rs.406 crore

Mumbai, Oct 30 : Drug maker Lupin saw its consolidated net profit rising 39.8 percent in the second quarter to Rs.406.20 crore, driven by other income, despite higher tax rate.

Consolidated revenue of the company grew 16 percent year-on-year (Y-o-Y) to Rs.2,668 crore in quarter ended September 2013, supported by formulations business and strong growth US, Europe and Africa, the company said in a release.

"Despite challenges in markets like India, we have had a good first half, driven by strong business growth from markets like US and improved operational efficiencies... This consistent performance has led to a sustained EBIDTA and PAT improvement," Nilesh Gupta, managing director, said.

Consolidated earnings before interest, tax, depreciation and amortisation (EBITDA) climbed 27.9 percent Y-o-Y to Rs.660 crore and operating profit margin expanded 230 basis points Y-o-Y to 24.7 percent in the quarter gone by.

Formulations business of the company grew 17 percent while Active pharmaceutical ingredient or API (drug raw material) shot up 20 percent Y-o-Y.

--IANS (Posted on 30-10-2013)

pharmaceutical-news headlines

US pharmaceutical giant Pfizer keen to acquire AstraZeneaca for $100 billion

Sanofi appoints N Rajaram as Country Head & GM (Pharma operations)

Nutraceuticals slams FSSAI 'Product Approval' scheme

Some facts about drug over which Powell banned

Lupin gets USFDA nod for diabetes management drug

Sun Pharma to acquire Ranbaxy for USD four billion in all stock transaction

Sun Pharma to buy Ranbaxy for $4 billion in all-share deal

Venus gets marketing nod from Venezuela for meropenem

Venus gets marketing nod from Venezuela for infection drug

Jubilant Life to develop new drugs to combat TB

Jubilant gets $3.4 mn for new anti-TB drugs

Prolonged crisis in Ukraine could affect Indian pharma companies

Quick Links: Goa | Munnar | Pondicherry | Free Yearly Horoscope '2014


Your e-mail:

Your Full Name:

Type verification image:
verification image, type it in the box


Back to Top